News & Updates

Show Multimedia Only

CSP vs BVP: Which one is better for HFrEF with non-LBBB?

20 Aug 2025 by

In a meta-analysis comparing procedural and clinical outcomes between conduction system pacing (CSP) and biventricular cardiac resynchronization pacing (BVP), the former appears to outdo the latter for managing individuals with heart failure with reduced ejection fraction (HFrEF) without left bundle branch block (LBBB).

CSP vs BVP: Which one is better for HFrEF with non-LBBB?

20 Aug 2025

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

20 Aug 2025

Monotherapy with rivaroxaban in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) appears to protect against the risks of major adverse cardiovascular event (MACE) and major bleeding, with the benefit observed across the broad range of age, according to a post hoc analysis of the open-label AFIRE* trial.

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

20 Aug 2025

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

20 Aug 2025 by

The American Heart Association defines cardiovascular-kidney-metabolic (CKM) syndrome as the overlap between metabolic, kidney, and cardiovascular diseases (CVDs). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, offer benefits that extend beyond glycaemic control and weight loss to cardiorenal protection. In a symposium, Dr Julie Lovshin of the University of Toronto, Canada, shared clinical trial data on once-weekly subcutaneous (SC) semaglutide’s cardiorenal protective effects in different CKM patient populations. She also explored characteristics of optimal candidates for GLP-1 RA treatment.

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

20 Aug 2025

First experience with sotatercept for pulmonary arterial hypertension in Southern China

20 Aug 2025 by

A 77-year-old male chronic smoker with a history of diabetes mellitus, hypertension, coronary artery disease treated with stenting to left circumflex artery and ramus intermediate artery in 2015, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) presented on 19 January 2024 with shortness of breath (SOB) on exertion, which began following an episode of COVID-19 in May 2023 and worsened after a subsequent COVID-19 episode in April 2024. Before the two COVID-19 episodes, the patient had good exercise tolerance and could manage a 1-hour hike.

First experience with sotatercept for pulmonary arterial hypertension in Southern China

20 Aug 2025

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025 by

Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic, progressive disorder associated with adverse outcomes in advanced stages. At an industry-sponsored symposium organized by the Hong Kong College of Family Physicians, experts discussed recommendations in the American Heart Association’s (AHA) presidential advisory on CKM health, strategies for early CKM intervention in primary care, as well as guideline recommendations and clinical trial results supporting the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i; eg, empagliflozin) in CKM syndrome.

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025

Sotatercept: A first-in-class PAH medication approved in HK

20 Aug 2025

Sotatercept, a first-in-class activin signalling inhibitor for pulmonary arterial hypertension (PAH), is approved in Hong Kong in August 2025, following regulatory approvals in Macau, the US, and the EU in February 2025.

Sotatercept: A first-in-class PAH medication approved in HK

20 Aug 2025

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

New drug applications approved by US FDA as of 16-31 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

Longer lactation duration tied to lower maternal CAD, stroke risks

18 Aug 2025

Extended durations of lactation appear to reduce the risk of maternal coronary artery disease (CAD) diagnosed before age 70 years, according to a study.

Longer lactation duration tied to lower maternal CAD, stroke risks

18 Aug 2025

Dapagliflozin plus spironolactone improves outcomes in HFpEF

17 Aug 2025

Combined treatment with dapagliflozin and spironolactone results in greater reductions in N-terminal pro–B-type natriuretic peptide (NT-proBNP) than dapagliflozine alone in patients with heart failure with preserved ejection fraction (HFpEF), a recent study has shown.

Dapagliflozin plus spironolactone improves outcomes in HFpEF

17 Aug 2025

Hypertension in pregnancy may be a risk factor for Alzheimer’s disease in Asians

16 Aug 2025 by

Women with a history of hypertensive disorders in pregnancy are at increased risk of developing brain changes that lead to Alzheimer’s disease (AD), according to a study from Singapore.

Hypertension in pregnancy may be a risk factor for Alzheimer’s disease in Asians

16 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

CSP vs BVP: Which one is better for HFrEF with non-LBBB?

CSP vs BVP: Which one is better for HFrEF with non-LBBB?

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

First experience with sotatercept for pulmonary arterial hypertension in Southern China

First experience with sotatercept for pulmonary arterial hypertension in Southern China

CKM syndrome: Strategies for early intervention in primary care

CKM syndrome: Strategies for early intervention in primary care

Sotatercept: A first-in-class PAH medication approved in HK

Sotatercept: A first-in-class PAH medication approved in HK

Original New Drug Application Approvals by US FDA (16-31 July 2025)

Original New Drug Application Approvals by US FDA (16-31 July 2025)

Longer lactation duration tied to lower maternal CAD, stroke risks

Longer lactation duration tied to lower maternal CAD, stroke risks

Dapagliflozin plus spironolactone improves outcomes in HFpEF

Dapagliflozin plus spironolactone improves outcomes in HFpEF

Hypertension in pregnancy may be a risk factor for Alzheimer’s disease in Asians

Hypertension in pregnancy may be a risk factor for Alzheimer’s disease in Asians